First Human Cell Vector Safety Testing Service To Be Launched
Brunel University, London spin-out Testavec Ltd will launch its hingetox vector safety testing service at the Oxford Global Online Conference on Gene Therapy in May.(5-6)
hingetox was developed from research funded under the NC3RS Crackit programme supported by Glaxo Smith Kline and Novartis as well as Brunel University. After over £1million ($1.4million) of investment in process development, Testavec can now offer a testing system that has the following major advantages. Tests can be run on the effect of vectors on human cells. The need for animals can be reduced or eliminated. Potential problems can rapidly be observed utilising an in-vitro testing system.
Benefits for Vector Developers
Historically mice have been used for vector testing and they do not perfectly replicate human reactions, in addition, the effects can take up to 18 months to be assessed. The hingetox system can start to yield results in 6 months providing the vector developer an early warning if there are problems. This time saving can translate into savings of literally millions of dollars as problems can be spotted early and equally confidence in a vector’s performance can be enhanced if results are positive, enabling earlier validation for ongoing investment.
Testavec can also test for vector impurities and can assess the ability of cells to repair their DNA.
Dr Mike Themis developer of the hingetox system in collaboration with Dr Manfred Schmidt of Genewerk GMBH says “ the future for Gene Therapy is very exciting and with the development of the hingetox system we can help companies who are designing vectors to get a much earlier feedback of their vector’s impact on human cells”
For Further Information
Professor Susan Jobling CEO - 07881 360800
Dr Michael Themis CSO - 07496 691591